Network
Media Magelang - The efficacy of the Pfizer BioNTech COVID-19 vaccine dropped to 84 per cent six months after the second dose, as the company’s CEO Albert Bourla quoted the latest finding from the company-funded research.
The research revealed that the effectiveness of Pfizer BioNTech hit its peak (96.1 percent) between one week and two months after the second jab. Every two months, the efficacy falls.
The latest study on the Pfizer vaccine triggers the assumption that everyone will get a third dose amid the quick spread of the highly transmissible Delta variant, which had spread to more than 104 countries as the World Health Organization (WHO) data showed as of 25 July.
Baca Juga: People Tend To Compare COVID-19 Vaccines, Which One Is the Most Effective? Here's The Explaination
Meanwhile, a study in Israel showed that the efficacy of the Pfizer shot against the Delta strain dropped to 39 per cent after the initial research showed that the efficacy fell to 64 per cent.
Such a result contradicts the research from the New England Journal of Medicine that Pfizer was 88 per cent effective against the Delta variant and 94 per cent against the original virus strain.
Behind the different data in Pfizer’s efficacy
According to researcher and medical practitioner Dr Jacob Wesley Ulm, MD, PhD, the Israeli data is more comprehensive as it also tracked the numbers of breakthrough infections (people who are infected with COVID-19 after receiving vaccination).
